Ardent Health Partners Inc’s filing revealed that its Director Webb Robert Thomas acquired Company’s shares for reported $0.34 million on Nov 08 ’24. In the deal valued at $16.98 per share,20,000 shares were bought. As a result of this transaction, Webb Robert Thomas now holds 40,275 shares worth roughly $0.57 million.
A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early November from “a Buy” to “a Neutral”. KeyBanc Capital Markets began covering ARDT with “an Overweight” recommendation on October 11, 2024. Truist started covering the stock on August 12, 2024. It rated ARDT as “a Buy”.
Price Performance Review of ARDT
On Tuesday, Ardent Health Partners Inc [NYSE:ARDT] saw its stock fall -12.46% to $14.05. Over the last five days, the stock has lost -11.75%. Ardent Health Partners Inc shares have fallen nearly -17.74% since the year began.
Levels Of Support And Resistance For ARDT Stock
The 24-hour chart illustrates a support level at 13.37, which if violated will result in even more drops to 12.70. On the upside, there is a resistance level at 15.35. A further resistance level may holdings at 16.66. The Relative Strength Index (RSI) on the 14-day chart is 31.10, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.94, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.50%. Stochastics %K at 14.33% indicates the stock is a buying.
How much short interest is there in Ardent Health Partners Inc?
A steep rise in short interest was recorded in Ardent Health Partners Inc stocks on 2024-12-31, growing by 0.95 million shares to a total of 1.65 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 0.7 million shares. There was a rise of 57.34%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 12, 2024 when Stephens began covering the stock and recommended ‘”an Overweight”‘ rating along with a $24 price target.
